Skip to content
OpenCapital
Get started

PROCEPT BioRobotics Corporation PRCT Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

Other financials

Income statement

See full
Revenue$83.1M+20.2%
Gross profit$53.9M+22.2%
Operating income-$32.6M-18.8%
Net income-$31.6M-27.9%
EPS (diluted)-$0.56-24.4%

Balance sheet

See full
Cash & equivalents$12.2M-96.2%
Total debt$78.0M-11.8%
Total equity$347.7M-10.7%
Total assets$487.1M-6.2%

Cash flow

See full
Operating cash flow-$38.1M-125%
CapEx$2.9M+58.7%
Free cash flow-$41.0M-118%

Valuation

See full
Market cap$1.19B-22.5%
Enterprise value$1.25B—
P/S3.7×—

Profitability

See full
Gross margin64%+1.3pp
Operating margin-33.9%-3.8pp
Net margin-31.8%-3.4pp
FCF margin-25%-5.7pp

Returns & leverage

See full
Return on equity-27.8%+0.2pp
Debt / equity0.2×0.0×
Current ratio6.7×-2.2×

Where this comes from

Reported directly by PROCEPT BioRobotics Corporation in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue.

The official record: PROCEPT BioRobotics Corporation’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about PROCEPT BioRobotics Corporation's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PROCEPT BioRobotics Corporation's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value?
PROCEPT BioRobotics Corporation (PRCT) reported share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value of $44.7M in Q1 2026.
How has PROCEPT BioRobotics Corporation's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value changed year-over-year?
PROCEPT BioRobotics Corporation's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value decreased by 72.5% year-over-year, from $162.3M to $44.7M.
What is the long-term trend for PROCEPT BioRobotics Corporation's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value?
Over 5 years (2020 to 2025), PROCEPT BioRobotics Corporation's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value has grown at a 54.6% compound annual growth rate (CAGR), from $6.9M to $61M.